ABN Amro Investment Solutions Purchases Shares of 1,745 United Therapeutics Corporation $UTHR

ABN Amro Investment Solutions purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,745 shares of the biotechnology company’s stock, valued at approximately $850,000.

A number of other hedge funds have also recently bought and sold shares of the stock. IFP Advisors Inc grew its stake in United Therapeutics by 11.8% in the fourth quarter. IFP Advisors Inc now owns 1,738 shares of the biotechnology company’s stock valued at $847,000 after purchasing an additional 184 shares in the last quarter. PSP Research LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $526,000. Banque Cantonale Vaudoise bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $939,000. Cullen Frost Bankers Inc. boosted its stake in shares of United Therapeutics by 3,333.3% during the 4th quarter. Cullen Frost Bankers Inc. now owns 103 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 100 shares during the period. Finally, Fairtree Asset Management Pty Ltd boosted its stake in shares of United Therapeutics by 3.3% during the 4th quarter. Fairtree Asset Management Pty Ltd now owns 1,976 shares of the biotechnology company’s stock worth $963,000 after acquiring an additional 63 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Cantor Fitzgerald lifted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Bank of America lifted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $568.43 on Monday. The stock has a market capitalization of $24.13 billion, a PE ratio of 20.98, a P/E/G ratio of 1.84 and a beta of 0.60. The business has a fifty day moving average price of $563.25 and a two-hundred day moving average price of $512.08. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $6.63 earnings per share. On average, equities analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current year.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders sold 555,473 shares of company stock valued at $310,786,074. 8.60% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.